Granules India CEO Dr Kandiraju Venkata Sitaram Rao to step down
Advertisement
Hyderabad: Granules India has announced the resignation of Dr Kandiraju Venkata Sitaram Rao from the position of Joint Managing Director and CEO of the Company due to personal reasons. His resignation shall be effective from the close of business hours on July 31, 2025, upon which he will also cease to be the Key Managerial Personnel (KMP) of the Company.
According to the company’s filing on the BSE, "Dr. Kandiraju Venkata Sitaram Rao (DIN: 08874100) shall cease to be the Joint Managing Director & CEO of the Company upon his resignation from the position. He shall also cease to be the Key Managerial Personnel (KMP) of the Company. His resignation shall be effective from the closure of business hours on July 31, 2025."
Dr. K.V.S. Ram Rao joined Granules in 2022. Prior to granules, he worked as Executive Director & CEO for CSM Business of PI Industries Limited. He played a significant role in Dr. Reddy’s Laboratories Limited while working in various capacities from 2000 to 2018. He also worked with Jubilant Life Sciences and Gujarat Heavy Chemicals Ltd.
Dr. Rao is well known for leadership capability in making high stake decisions and overcoming complex business challenges and is expert at articulating and implementing change while gaining consensus from people with differing agenda. He established innovative business models with eminent team dynamics and instituted good manufacturing and R&D systems. He also built best in class practices in environment, health & safety and nurtured excellent diversity & inclusivity policies. He has strong market knowledge, financial/analytical skills, customer-oriented approach, industry network at multiple levels, well-grounded principles of governance & ethics.
He holds a bachelor’s degree in chemical engineering from Osmania University, Hyderabad and a master’s degree & Ph.D. in chemical engineering from Indian Institute of Science, Bangalore.
Granules products are being distributed to over 300+ customers in regulated and semi-regulated markets with a global presence extending to over 80+ countries with offices across India, US, and UK. The Company has 10 manufacturing facilities out of which 8 are in India and 2 in the USA and has regulatory approvals from US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC, and HALAL.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.